This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.
Speaking for myself and not for anyone else who has posted here.
Marking my uncertainty on CJC-1295 explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it generalises past the case in the first post.
Confirming post #60 from a second method, which matters more than confirming it from a second person.
CJC-1295 is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty minutes before adding to this one.
I had written a reply contradicting post #62 and deleted it. Here is what survived.
Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.
I am reporting what happened, not recommending it.
Reading rather than answering, but this is the post I would point somebody at.
Storage: these are lyophilised short peptides and are generally reasonably stable dry and considerably less so in solution. Reconstituting only what will be used within the period the supplier's own data covers is the conservative approach.
I would want the raw data before agreeing with my own summary of it.
On CJC-1295: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
Answering the question post #66 raises rather than the one it answers.
GHRH analogues versus ghrelin mimetics are often conflated but they are different mechanisms. GHRH analogues (like CJC-1295) cause the pituitary to release growth hormone. Ghrelin mimetics (like GHRPs) act on the ghrelin receptor directly. The effect on growth hormone secretion is similar but the mechanisms are distinct.
I had written a reply contradicting post #69 and deleted it. Here is what survived.
On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.
That is one dataset and I would not build a rule on it.
Reading a rodent study on a secretagogue without over-extrapolating: rodent studies can show a mechanism is plausible. They cannot show magnitude of effect in humans or safety profile in humans. That gap is larger for secretagogues than for incretin agonists because the human evidence is thinner.
Picking up post #73: that is the part I would want checked first.
The version of CJC-1295 that I was taught turned out to be a teaching simplification. Useful, and not true in the way I had assumed it was.
CJC-1295 with and without DAC: the version with a drug affinity complex binds albumin covalently and persists for days. The version without it does not persist. Supplier labelling frequently does not distinguish them clearly, so confirming which you have is important.
Worth separating two things that post #73 runs together.
CJC-1295 is a good example of a question where the honest answer is boring and the interesting answers are unsupported. I would go with boring.
What I want from this CJC-1295 thread is the list of things that would need to be true for the claim to hold. If we can write that list, we can check it.
Understood, and I withdraw the assumption I opened with.
Post #80 put the caveat in the right place and I want to underline it.
Two sentences on CJC-1295 and then I will stop, because the rest is speculation and the thread is better without mine.
What is documented is narrow. What is inferred from it is broad. The gap between them is where every argument here lives.
A purity figure without a method for a short peptide is nearly uninterpretable, because short peptides can be run on gradients that resolve almost nothing and still produce a clean-looking trace.
The claim about CJC-1295 upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
Post #84 and I disagree about the size of the effect, not about the direction.
A mass result for a short peptide is more discriminating than for a long one, because a single residue difference is a larger proportion of the total. That makes identity confirmation genuinely useful here.
Noting that I have skin in this question and have tried to discount for it.
Narrowing post #86, because the general version has more than one answer.
An observation about CJC-1295 that I cannot explain and am posting anyway, on the principle that unexplained observations are more useful public than private.
Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.